• By ICR Secretariat
  • Posted Wednesday, January 15, 2020

Blueprint wins 1st FDA approval with targeted cancer drug

https://www.biopharmadive.com/news/blueprint-Ayvakit-FDA-approval-GIST-cancer/570223/

Boston-based Blueprint Medicines on Thursday won its first-ever drug approval, securing clearance from the Food and Drug Administration for its genetically targeted cancer therapy Ayvakit in an ultra-rare type of tumor known as GIST.